GATA 3 Expression in Breast Carcinoma and Its Association with ER, PR, HER 2NEU STATUS: A Three Years Study in a Tertiary Care Centre

INTRODUCTION: Some recent studies has shown that expression of GATA-3 is limited to carcinoma of breast and carcinoma of urinary bladder and therefore this IHC marker may be a sensitive and specific marker for metastatic breast carcinomas. METHODS: In this study, to evaluate the expression of GATA-3 in breast carcinoma and to compare the GATA-3 expression with already known ER, PR and HER 2 neu status of breast carcinoma cases. MATERIALS AND METHODS: This is a study of both prospective and retrospective type for a period of 3 years. For our study we did IHC test for 50 cases of invasive breast carcinoma with already known ER, PR and HER 2 NEU status. OBSERVATION AND RESULTS: In our study out of 50 cases 36 (72%) showed GATA 3 reactive and 14 cases (28%) cases were negative and 36 (72%) case showed positive result. Among the luminal subtype 91% showed GATA3 positivity and 2 cases (9%) showed negative reaction to. CONCLUSION: From the study it is found that GATA3 may not be shown to be a prognostic factor. GATA 3 expression in triple negative tumors may be an important clue to establish this marker for metastatic breast carcinoma (MBC)